Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/15/24
Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.Investors Business Daily • 02/15/24
Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 02/12/24
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/08/24
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024PRNewsWire • 02/01/24
VantAI Secures Renewed Support from Blueprint Medicines to Chart New Frontiers in Induced Proximity Drug DiscoveryBusiness Wire • 01/09/24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/08/24
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic MastocytosisPRNewsWire • 12/12/23
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual MeetingPRNewsWire • 12/09/23
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic MastocytosisPRNewsWire • 11/10/23
How Much Upside is Left in Blueprint Medicines (BPMC)? Wall Street Analysts Think 42.16%Zacks Investment Research • 10/31/23
Compared to Estimates, Blueprint Medicines (BPMC) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/26/23